



AOCG Memo No. 5 - 2025

REPUBLIC OF THE PHILIPPINES DEPARTMENT OF FINANCE BUREAU OF CUSTOMS

A modernized and credible customs administration that upholds good governance and is among the world's best

MEMORANDUM

TO

ALL DISTRICT and SUB-PORT COLLECTORS

ALL CHIEFS, FORMAL ENTRY DIVISION

AND FORMAL ENTRY DIVISION PERSONNEL

FROM

ATTY. VENER S. BAQUIRAN

Deputy Commissione

Assessment and Operations Coordinating Group (AOCG)

SUBJECT

TARIFF COMMISSION CIRCULARS/ADVANCE RULINGS

(TCC/AR)

DATE

03 January 2025

Pursuant to the provisions of Section 1603 (f) of the Customs Modernization and Tariff Act (Republic Act 10863) and Section 4.9 of Commission Order No. 2017-1 (Procedure on Application for an Advance Ruling on Tariff Classification related to Importation of Goods), the Tariff Commission furnished copies of the Advance Ruling (AR) on Tariff Classification with Tariff Classification Circulars (TCC/AR) issued on 26 December 2024 and the same having been reviewed and summarized as follows:

TCC. NO.	DESCRIPTION OF ARTICLES	2022 AHTN CODE	2024 RATES OF DUTY
24-788	"MASTIPLAN® LC"	3004.20.99	MFN – 5% ad valorem
24-795	"PBAC SUPER-Q"	3004.20.10	MFN – 5% ad valorem ATIGA – Zero* AANZFTA – Zero* ACFTA – Zero* AHKFTA – Zero* AIFTA – Zero* AJCEPA – Zero* AKFTA – Zero* RCEP – Zero*

*Subject to submission of their corresponding CERTIFICATES OF ORIGIN (COs).





REPUBLIC OF THE PHILIPPINES **DEPARTMENT OF FINANCE BUREAU OF CUSTOMS**

TCC. NO.	DESCRIPTION OF ARTICLES	2022 AHTN CODE	2024 RATES OF DUTY
24-803	"PBAC ZOLTRIM 480"	3004.20.10	MFN – 5% ad valorem ATIGA – Zero* AANZFTA – Zero* ACFTA – Zero* AHKFTA – Zero* AIFTA – Zero* AJCEPA – Zero* AKFTA – Zero* RCEP – Zero*
24-811	"STAFAC® 110"	3003.20.00	MFN – 3% ad valorem
24-832	"SULPRIM COX EMV"	3004.20.10	MFN – 5% ad valorem ATIGA – Zero* AANZFTA – Zero* ACFTA – Zero* AHKFTA – Zero* AIFTA – Zero* AJCEPA – Zero* AKFTA – Zero* RCEP – Zero*
24-835	"ENROCOLI EMV"	3004.20.91	MFN – 5% ad valorem ATIGA – Zero* AANZFTA – Zero* ACFTA – Zero* AHKFTA – Zero* AIFTA – Zero* AJCEPA – Zero* AKFTA – Zero* RCEP – Zero*
24-887	"MOMETAMAX ULTRA"	3004.20.99	MFN – 5% ad valorem
*Subject to submission of their corresponding CERTIFICATES OF ORIGIN (COs).			

For information, guidance and strict compliance.

CC: COMMISSIONER OF CUSTOMS









TARIFF COMMISSION

Ref. No. 24-122

26 December 2024

COMMISSIONER BIENVENIDO Y. RUBIO

Bureau of Customs G/F OCOM Building 16th Street, South Harbor Gate 3 Port Area, Manila

Dear Commissioner Rubio:

Pursuant to the provisions of Section 1603(f) of the Customs Modernization and Tariff Act (Republic Act No. 10863) and Section 4.9 of Commission Order No. 2017-1 (Procedure on Application for an Advance Ruling on Tariff Classification Related to Importation or Exportation of Goods), this Commission is pleased to furnish your good Office with PDF copies of seven Advance Rulings on Tariff Classification, with TCC (AR) Nos. 24-788, 24-795, 24-803, 24-811, 24-832, 24-835, and 24-887, issued by this Commission on 26 December 2024. These Advance Rulings have also been posted on the Commission's website www.tariffcommission.gov.ph.

Thank you.

Very truly yours,

MARILOU P. MENDOZA

Chairperson

Encl: As stated

cc: The Secretary

Department of Finance

Manila







Tariff Commission

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

> AHTN 3004.20.99 MFN - 5% ad valorem

2	TCC (AR) NO.
	24-788
3	DATE ISSUED

4 DESCRIPTION OF GOOD

"MASTIPLAN® LC"

Based on the brochure, package insert, product label, and photograph of the packaging submitted, subject article is an antibacterial and corticosteroid intramammary suspension, containing 300 mg cefapirin sodium and 20 mg prednisolone per 8 g of suspension. It is indicated for the treatment of clinical mastitis in lactating dairy cows caused by *Staphylococcus aureus*, Coagulase negative *staphylococci*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus uberis*, and *Escherichia coli* sensitive to cefapirin. Subject article is available in boxes containing four or 20 pieces of laminated aluminium foil sachets, with each sachet containing one 10-mL polyethylene intramammary syringe closed with a cap, a plunger, and a cleaning towel. It is administered by infusing the contents of one syringe into each affected quarter via the teat canal, immediately after milking, at 12-hour intervals, for four consecutive milkings.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm³, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem.

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Travil P Tunky

MARILOU P. MENDOZA

Chairperson









TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

AHTN 3004.20.10

MFN - 5% ad valorem AANZFTA - Zero AHKFTA - Zero AJCEPA - Zero RCEP - Zero ATIGA - Zero ACFTA - Zero AIFTA - Zero AKFTA - Zero

4 DESCRIPTION OF GOOD

"PBAC SUPER-Q"

Based on the Certificate of Product Registration from the Bureau of Animal Industry (BAI), product composition, safety data sheet, and product label submitted, subject article is an antibacterial/anti-infective medicated solution containing 100 mg enrofloxacin and 50 mg lincomycin per milliliter of solution. Packed in 1-L plastic bottles, subject article is added at a dosage of 0.5 mL per liter of drinking water of poultry, for three to 10 consecutive days, for the treatment of chronic respiratory disease, colibacillosis, salmonellosis, fowl cholera, enteritis, and other infections caused by susceptible gram-positive and gram-negative aerobic and anaerobic bacteria and by *Mycoplasma*.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, in packings for retail sale for therapeutic or prophylactic use. This refers to products (for example, sodium bicarbonate and tamarind powder) which, because of their packing and, in particular, the presence of appropriate indications (statement of disease or condition for which they are to be used, method of use or application, statement of dose, etc.) are clearly intended for sale directly to users (private persons, hospitals, etc.) without repacking, for the above purposes. These indications (in any language) may be given by label, literature or otherwise.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.10, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and the following applicable rates of duty under the various Philippine free trade agreements (FTA), subject to submission of the corresponding proof of origin:





AOCG Memo No. 3-2025 P. 6

2	TCC (AR) NO.
	24-795

Free Trade Agreement	Applicable Rates of Duty (%, ad valorem)	Proof of Origin
ASEAN Trade in Goods Agreement (ATIGA)	0	Certificate of Origin (CO) Form D, Electronic Certificate of Origin (e-Form D), or Origin Declaration by Approved Exporter
ASEAN-Australia-New Zealand Free Trade Area (AANZFTA)	0	CO Form AANZ
ASEAN-China Free Trade Area (ACFTA)	0	CO Form E
ASEAN-Hong Kong, China Free Trade Agreement (AHKFTA)	0	CO Form AHK
ASEAN-India Free Trade Area (AIFTA)	0	CO Form AI
ASEAN-Japan Comprehensive Economic Partnership Agreement (AJCEPA)	0	CO Form AJ
ASEAN-Korea Free Trade Area (AKFTA)	0	CO Form AK
Regional Comprehensive Economic Partnership (RCEP) Agreement	0	CO Form RCEP or Declaration of Origin (DO) issued by an Approved Exporter


This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

MARILOU P. MENDOZA

Chairperson





1



REPUBLIC OF THE PHILIPPINES

Tariff Commission

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

AHTN 3004.20.10

MFN - 5% ad valorem

AANZFTA - Zero AHKFTA - Zero

ACFTA - Zero AIFTA - Zero

ATIGA - Zero

AJCEPA - Zero

RCEP - Zero

AKFTA - Zero

2	TCC (AR) NO.
	24-803
3	DATE ISSUED

26 December 2024

DESCRIPTION OF GOOD

"PBAC ZOLTRIM 480"

Based on the Certificate of Product Registration from the Bureau of Animal Industry (BAI), brochure, product composition, safety data sheet, and product label submitted, subject article is an antibacterial/anti-infective medicated suspension containing 400 mg sulfamethoxazole and 80 mg trimethoprim per milliliter of suspension. Packed in 1-L plastic bottles, subject article is administered at the recommended dosage via drinking water of swine and poultry, for the treatment of respiratory, alimentary, and urinary tract infections, and of wound infections caused by susceptible bacteria including colibacillosis, salmonellosis, pasteurellosis, coccidiosis, pneumonia, and fowl cholera.

REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, in packings for retail sale for the rapeutic or prophylactic use. This refers to products (for example, sodium bicarbonate and tamarind powder) which, because of their packing and, in particular, the presence of appropriate indications (statement of disease or condition for which they are to be used, method of use or application, statement of dose, etc.) are clearly intended for sale directly to users (private persons, hospitals, etc.) without repacking, for the above purposes. These indications (in any language) may be given by label, literature or otherwise.

In view thereof, subject article is classified under AHTN 2022 subheading 3004,20,10, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and the following applicable rates of duty under the various Philippine free trade agreements (FTA), subject to submission of the corresponding proof of origin:





AOCG Memo No. 3-2025 P. 8

2	TCC (AR) NO.
	24-803

Free Trade Agreement	Applicable Rates of Duty (%, ad valorem)	Proof of Origin
ASEAN Trade in Goods Agreement (ATIGA)	0	Certificate of Origin (CO) Form D, Electronic Certificate of Origin (e-Form D), or Origin Declaration by Approved Exporter
ASEAN-Australia-New Zealand Free Trade Area (AANZFTA)	0	CO Form AANZ
ASEAN-China Free Trade Area (ACFTA)	0	CO Form E
ASEAN-Hong Kong, China Free Trade Agreement (AHKFTA)	0	CO Form AHK
ASEAN-India Free Trade Area (AIFTA)	0	CO Form AI
ASEAN-Japan Comprehensive Economic Partnership Agreement (AJCEPA)	0	CO Form AJ
ASEAN-Korea Free Trade Area (AKFTA)	0	CO Form AK
Regional Comprehensive Economic Partnership (RCEP) Agreement	0	CO Form RCEP or Declaration of Origin (DO) issued by an Approved Exporter


This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Trail P Truly

MARILOU P. MENDOZA

Chairperson







TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

> AHTN 3003.20.00 MFN - 3% ad valorem

2	TCC (AR) NO.
	24-811
3	DATE ISSUED
2	26 December 2024

4 DESCRIPTION OF GOOD

"STAFAC® 110"

Based on the Certificate of Product Registration from the Bureau of Animal Industry (BAI), brochure, manufacturing process, safety data sheet, and photograph of the packaging submitted, subject article is an antibacterial feed premix powder. It consists of virginiamycin (active ingredient), rice hulls, and calcium carbonate, among others. Packed in 25-kg bags, subject article is to be mixed with animal feeds at a dosage depending on the animal's requirement, for, among others, prevention and treatment of necrotic enteritis in poultry caused by *Clostridium perfringens*; prevention, treatment, and control of swine dysentery; and reduction of liver abscess incidence in cattle.

5 REASONS FOR CLASSIFICATION

Heading 30.03 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicinal preparations for use in the internal or external treatment or prevention of human or animal ailments. These preparations are obtained by mixing together two or more substances.

In view thereof, subject article is classified under AHTN 2022 subheading 3003,20,00, with a Most Favoured Nation (MFN) rate of duty of 3% ad valorem.

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.


FOR THE COMMISSION

Lank P Lundige

MARILOU P. MENDOZA

Chairperson









Tariff Commission

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

AHTN 3004,20,10

MFN - 5% ad valorem

AANZFTA - Zero

AHKFTA - Zero

AJCEPA - Zero

RCEP - Zero

ATIGA - Zero

ACFTA - Zero

AIFTA - Zero

AKFTA - Zero

26 December 2024

TCC (AR) NO.

DATE ISSUED

24-832

2

3

DESCRIPTION OF GOOD

"SULPRIM COX EMV"

Based on the Certificate of Product Registration from the Bureau of Animal Industry (BAI), brochure, product composition, certificate of analysis, and material safety data sheet submitted, subject article is an antibacterial/anti-infective medicated suspension containing 400 g sulfamethoxazole and 80 g trimethoprim per liter of suspension. Packed in 500-mL and 1-L plastic bottles, subject article is administered via drinking water of swine and poultry, at the recommended dosage, for the treatment of *E. coli* infection, salmonellosis, fowl cholera, infectious coryza, and salpingitis in poultry, and for the treatment of gastrointestinal, urinary, and respiratory tract infections in swine, caused by *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, and *Pasteurella multocida*, among others.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, in packings for retail sale for therapeutic or prophylactic use. This refers to products (for example, sodium bicarbonate and tamarind powder) which, because of their packing and, in particular, the presence of appropriate indications (statement of disease or condition for which they are to be used, method of use or application, statement of dose, etc.) are clearly intended for sale directly to users (private persons, hospitals, etc.) without repacking, for the above purposes. These indications (in any language) may be given by label, literature or otherwise.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.10, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and the following applicable rates of duty under the various Philippine free trade agreements (FTA), subject to submission of the corresponding proof of origin:





AOCG Memo No. 5-2025 P. 11

2	TCC (AR) NO.
	24-832


Free Trade Agreement	Applicable Rates of Duty (%, ad valorem)	Proof of Origin
ASEAN Trade in Goods Agreement (ATIGA)	. 0	Certificate of Origin (CO) Form D, Electronic Certificate of Origin (e-Form D), or Origin Declaration by Approved Exporter
ASEAN-Australia-New Zealand Free Trade Area (AANZFTA)	0	CO Form AANZ
ASEAN-China Free Trade Area (ACFTA)	0	CO Form E
ASEAN-Hong Kong, China Free Trade Agreement (AHKFTA)	0	CO Form AHK
ASEAN-India Free Trade Area (AIFTA)	0	CO Form AI
ASEAN-Japan Comprehensive Economic Partnership Agreement (AJCEPA)	0	CO Form AJ
ASEAN-Korea Free Trade Area (AKFTA)	0	CO Form AK
Regional Comprehensive Economic Partnership (RCEP) Agreement	0	CO Form RCEP or Declaration of Origin (DO) issued by an Approved Exporter

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

h F Trundy

MARILOU P. MENDOZA Chairperson







TARIFF COMMISSION

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

AHTN 3004,20,91

MFN - 5% ad valorem AANZFTA - Zero AHKFTA - Zero AJCEPA - Zero RCEP - Zero ATIGA - Zero ACFTA - Zero AIFTA - Zero AKFTA - Zero

	24-835
3	DATE ISSUED

26 December 2024

4 DESCRIPTION OF GOOD

"ENROCOLI EMV"

Based on the Certificate of Product Registration from the Bureau of Animal Industry (BAI), brochure, product composition, certificate of analysis, and material safety data sheet submitted, subject article is an antibacterial/anti-infective solution in the form of a yellowish to yellow liquid solution. It contains enrofloxacin and colistin sulphate (active ingredients) with water (excipient). Packed in 100-mL, 200-mL, 500-mL, and 1-L plastic bottles, subject article is administered at the recommended dosage to poultry and swine via drinking water, for the treatment of infectious diseases caused by *Mycoplasma spp.*, *E. coli*, *Pasteurella spp.*, *Salmonella spp.*, and *Chlamydia spp.*, among others, in poultry, and for the treatment of colibacillosis and other gastrointestinal infectious diseases in swine.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, in packings for retail sale for therapeutic or prophylactic use. This refers to products (for example, sodium bicarbonate and tamarind powder) which, because of their packing and, in particular, the presence of appropriate indications (statement of disease or condition for which they are to be used, method of use or application, statement of dose, etc.) are clearly intended for sale directly to users (private persons, hospitals, etc.) without repacking, for the above purposes.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.91, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem and the following applicable rates of duty under the various Philippine free trade agreements (FTA), subject to submission of the corresponding proof of origin:





AOCG Memo No. 5-2025 P - 13

2	TCC (AR) NO.
	24-835

Free Trade Agreement	Applicable Rates of Duty (%, ad valorem)	Proof of Origin
ASEAN Trade in Goods Agreement (ATIGA)	0	Certificate of Origin (CO) Form D, Electronic Certificate of Origin (e-Form D), or Origin Declaration by Approved Exporter
ASEAN-Australia-New Zealand Free Trade Area (AANZFTA)	0	CO Form AANZ
ASEAN-China Free Trade Area (ACFTA)	0	CO Form E
ASEAN-Hong Kong, China Free Trade Agreement (AHKFTA)	0	CO Form AHK
ASEAN-India Free Trade Area (AIFTA)	0	CO Form AI
ASEAN-Japan Comprehensive Economic Partnership Agreement (AJCEPA)	0	CO Form AJ
ASEAN-Korea Free Trade Area (AKFTA)	0	CO Form AK
Regional Comprehensive Economic Partnership (RCEP) Agreement	0	CO Form RCEP or Declaration of Origin (DO) issued by an Approved Exporter

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

Digitally signed

Thomas P Thomas Agent

MARILOU P. MENDOZA

Chairperson







Tariff Commission

ADVANCE RULING ON TARIFF CLASSIFICATION

Pursuant to Section 1100 of RA 10863 (CMTA)

AHTN 2022 CODE AND 2024 AND 2025 RATE/S OF IMPORT DUTY

> AHTN 3004.20.99 MFN - 5% ad valorem

2	TCC (AR) NO.
	24-887
3	DATE ISSUED

4 DESCRIPTION OF GOOD

"MOMETAMAX ULTRA"

Based on the brochure, manufacturing and filling process flow diagram, product information sheet, and package insert submitted, subject article is an antibacterial/corticosteroid/antifungal ear drops suspension for dogs containing 6.88 mg gentamicin (antibacterial), 1.68 mg mometasone furoate (corticosteroid), and 2.08 mg posaconazole (antifungal) per 0.8 mL of suspension. It is indicated for the treatment of otitis externa caused by susceptible strains of bacteria sensitive to gentamicin (*Staphylococcus pseudintermedius, Streptococcus canis, Pseudomonas aeruginosa, Escherichia coli,* and *Proteus mirabilis*) and fungi susceptible to posaconazole (*Malassezia pachydermatis*). It is packed in a box containing one piece of 16-mL white high-density polyethylene (HDPE) bottle (sufficient for 20 doses of 0.8 mL) and 20 pieces of 1-mL capacity syringes (one with press-in bottle adapter attached). Using a syringe, subject article is administered at the entrance of the external ear of a dog, at a dosage of 0.8 mL per infected ear.

5 REASONS FOR CLASSIFICATION

Heading 30.04 of the ASEAN Harmonised Tariff Nomenclature (AHTN) 2022 covers medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale. The pertinent Harmonized System (HS) Explanatory Notes (EN) state that this heading covers medicaments consisting of mixed or unmixed products, provided they are, among others, put up in measured doses or in forms such as tablets, ampoules (for example, re-distilled water, in ampoules of 1.25 to 10 cm³, for use either for the direct treatment of certain diseases, e.g., alcoholism, diabetic coma or as a solvent for the preparation of injectible medicinal solutions), capsules, cachets, drops or pastilles, medicaments in the form of transdermal administration systems, or small quantities of powder, ready for taking as single doses for therapeutic or prophylactic use.

In view thereof, subject article is classified under AHTN 2022 subheading 3004.20.99, with a Most Favoured Nation (MFN) rate of duty of 5% ad valorem.

This ruling shall be valid for five years from the date of issuance and shall continue to apply unless the law, facts, or circumstances supporting this ruling have changed.

FOR THE COMMISSION

MARILOU P. MENDOZA

Chairperson

